CXCL9 and neoplasm: We, therefore, propose that serum CXCL10 concentrations may serve as a surrogate for tumor immune subtypes and that levels may fluctuate with serum CXCL9 concentrations, reflecting the extent of immune reconstitution by anti-angiogenic therapy.